Efficacy of docetaxel combined with oxaliplatin and capecitabine in palliative chemotherapy for advanced gastric cancer

Abstract

Objective To investigate the clinical efficacy of docetaxel combined with oxaliplatin and capecitabine in treating advanced gastric cancer. Methods 60 patients with advanced gastric cancer received neoadjuvant chemotherapy in our hospital from January 2011 to December 2016, whom were randomly divided into the control group (n=30) and the observation group (n=30). Patients in the control group was treated with oxaliplatin and capecitabine, while patients in the observation group was given docetaxel combined with oxaliplatin and capecitabine for palliative chemotherapy.Spss15.0 softwarewas used for data analysis.The short-term clinical outcomewere presented as mean+ standard deviation and were examined by using t test.The incidence of side effects were expressed as %, and were compared with χ2 test. P<0.05 was considered as significant difference. Results The remission rate in the control group was 26.7%, while the remission rate in the observation group was 56.7%.The time of progress and the survival time in the observation group were better than those in the control group respectively, with significant difference (P 0.05). Conclusion Therapeutic effect of docetaxel combined with oxaliplatin and capecitabine in the palliative chemotherapy of advanced gastric cancer is positive, with patient’s satisfaction. It is worthy of clinical application. Key words: Stomach neoplasms; Drug therapy, combination; Palliative care; Treatment outcome